After Amway CEO Milind Pant stated in a 2023 interview that his investment plan for India was “very bullish,” the company has announced it will spend $4 million on the construction of four Research & Development (R&D) labs across India. Collectively, the labs will encompass more than 24,000 square feet and will be located in Gurugram, Chennai, Bengaluru, and Dindigul. The labs are expected to focus on product solutions in the categories of foods, oral solids, beauty and personal care and will meet both domestic and global requirements.
“There is a need for a transformative approach to nutrition and wellness in India, as the health landscape here faces significant challenges related to nutrition, lifestyle and gut health,” said Rajneesh Chopra, Amway India Managing Director. “This investment accelerates Amway India’s product development capabilities and positions Amway to better serve the unique and evolving needs of its consumers and businesses in India and around the world. India stands as one of our top priority markets globally and this investment underscores the confidence of Amway Global in the country’s expertise and potential to drive groundbreaking innovation in the health and wellbeing space.”
